Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

OWLT vs LMAT vs NVCR vs ATRC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OWLT
Owlet, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$17.66B
5Y Perf.-96.4%
LMAT
LeMaitre Vascular, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$2.46B
5Y Perf.+174.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-86.6%
ATRC
AtriCure, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$1.41B
5Y Perf.-36.1%

OWLT vs LMAT vs NVCR vs ATRC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OWLT logoOWLT
LMAT logoLMAT
NVCR logoNVCR
ATRC logoATRC
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$17.66B$2.46B$1.92B$1.41B
Revenue (TTM)$107M$256M$674M$552M
Net Income (TTM)$-46M$62M$-173M$-5M
Gross Margin50.8%72.4%75.2%75.5%
Operating Margin-10.5%28.5%-27.2%-0.4%
Forward P/E37.2x370.7x
Total Debt$13M$186M$290M$88M
Cash & Equiv.$36M$28M$103M$167M

OWLT vs LMAT vs NVCR vs ATRCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OWLT
LMAT
NVCR
ATRC
StockNov 20May 26Return
Owlet, Inc. (OWLT)1003.6-96.4%
LeMaitre Vascular, … (LMAT)100274.0+174.0%
NovoCure Limited (NVCR)10013.4-86.6%
AtriCure, Inc. (ATRC)10063.9-36.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: OWLT vs LMAT vs NVCR vs ATRC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LMAT leads in 6 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Owlet, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
OWLT
Owlet, Inc.
The Growth Leader

OWLT is the #2 pick in this set and the best alternative if growth is your priority.

  • 35.4% revenue growth vs NVCR's 8.3%
Best for: growth
LMAT
LeMaitre Vascular, Inc.
The Income Pick

LMAT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 15 yrs, beta 0.57, yield 0.7%
  • 6.1% 10Y total return vs ATRC's 95.1%
  • Lower volatility, beta 0.57, Low D/E 47.2%, current ratio 12.89x
  • Beta 0.57, yield 0.7%, current ratio 12.89x
Best for: income & stability and long-term compounding
NVCR
NovoCure Limited
The Specific-Use Pick

NVCR plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ATRC
AtriCure, Inc.
The Growth Play

ATRC is the clearest fit if your priority is growth exposure.

  • Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthOWLT logoOWLT35.4% revenue growth vs NVCR's 8.3%
ValueLMAT logoLMATBetter valuation composite
Quality / MarginsLMAT logoLMAT24.3% margin vs OWLT's -42.5%
Stability / SafetyLMAT logoLMATBeta 0.57 vs NVCR's 2.20, lower leverage
DividendsLMAT logoLMAT0.7% yield; 15-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)LMAT logoLMAT+33.3% vs ATRC's -8.3%
Efficiency (ROA)LMAT logoLMAT10.3% ROA vs OWLT's -58.6%, ROIC 9.7% vs -48.1%

OWLT vs LMAT vs NVCR vs ATRC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OWLTOwlet, Inc.

Segment breakdown not available.

LMATLeMaitre Vascular, Inc.

Segment breakdown not available.

NVCRNovoCure Limited

Segment breakdown not available.

ATRCAtriCure, Inc.
FY 2025
Shipping and Handling
100.0%$2M

OWLT vs LMAT vs NVCR vs ATRC — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLMATLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

Evenly matched — LMAT and ATRC each lead in 3 of 6 comparable metrics.

NVCR is the larger business by revenue, generating $674M annually — 6.3x OWLT's $107M. LMAT is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to OWLT's -42.5%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
RevenueTrailing 12 months$107M$256M$674M$552M
EBITDAEarnings before interest/tax-$11M$81M-$165M$13M
Net IncomeAfter-tax profit-$46M$62M-$173M-$5M
Free Cash FlowCash after capex-$10M$79M-$48M$54M
Gross MarginGross profit ÷ Revenue+50.8%+72.4%+75.2%+75.5%
Operating MarginEBIT ÷ Revenue-10.5%+28.5%-27.2%-0.4%
Net MarginNet income ÷ Revenue-42.5%+24.3%-25.7%-0.8%
FCF MarginFCF ÷ Revenue-9.7%+30.9%-7.1%+9.7%
Rev. Growth (YoY)Latest quarter vs prior year+6.6%+11.2%+12.3%+14.3%
EPS Growth (YoY)Latest quarter vs prior year-3.3%+41.7%-100.0%+101.6%
Evenly matched — LMAT and ATRC each lead in 3 of 6 comparable metrics.

Valuation Metrics

ATRC leads this category, winning 4 of 6 comparable metrics.

On an enterprise value basis, LMAT's 33.4x EV/EBITDA is more attractive than ATRC's 77.7x.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
Market CapShares × price$17.7B$2.5B$1.9B$1.4B
Enterprise ValueMkt cap + debt − cash$17.6B$2.6B$2.1B$1.3B
Trailing P/EPrice ÷ TTM EPS-2.17x42.82x-13.80x-115.83x
Forward P/EPrice ÷ next-FY EPS est.37.17x370.67x
PEG RatioP/E ÷ EPS growth rate2.21x
EV / EBITDAEnterprise value multiple33.39x77.75x
Price / SalesMarket cap ÷ Revenue167.06x9.85x2.92x2.63x
Price / BookPrice ÷ Book value/share77.22x6.29x5.51x2.70x
Price / FCFMarket cap ÷ FCF33.01x29.15x
ATRC leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

LMAT leads this category, winning 6 of 9 comparable metrics.

LMAT delivers a 16.2% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-6 for OWLT. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), LMAT scores 7/9 vs OWLT's 4/9, reflecting strong financial health.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
ROE (TTM)Return on equity-5.9%+16.2%-50.8%-1.0%
ROA (TTM)Return on assets-58.6%+10.3%-16.5%-0.7%
ROICReturn on invested capital-48.1%+9.7%-16.4%-0.6%
ROCEReturn on capital employed-30.5%+12.3%-28.9%-0.6%
Piotroski ScoreFundamental quality 0–94755
Debt / EquityFinancial leverage0.37x0.47x0.85x0.18x
Net DebtTotal debt minus cash-$22M$157M$187M-$79M
Cash & Equiv.Liquid assets$36M$28M$103M$167M
Total DebtShort + long-term debt$13M$186M$290M$88M
Interest CoverageEBIT ÷ Interest expense-7.21x24.99x-96.80x0.47x
LMAT leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LMAT leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LMAT five years ago would be worth $21,818 today (with dividends reinvested), compared to $348 for OWLT. Over the past 12 months, LMAT leads with a +33.3% total return vs ATRC's -8.3%. The 3-year compound annual growth rate (CAGR) favors LMAT at 18.2% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
YTD ReturnYear-to-date-69.9%+34.9%+28.3%-29.2%
1-Year ReturnPast 12 months+17.4%+33.3%+1.1%-8.3%
3-Year ReturnCumulative with dividends+4.2%+65.2%-75.7%-41.8%
5-Year ReturnCumulative with dividends-96.5%+118.2%-91.3%-64.2%
10-Year ReturnCumulative with dividends-96.4%+608.6%+30.3%+95.1%
CAGR (3Y)Annualised 3-year return+1.4%+18.2%-37.6%-16.5%
LMAT leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LMAT leads this category, winning 2 of 2 comparable metrics.

LMAT is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LMAT currently trades 91.4% from its 52-week high vs OWLT's 28.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
Beta (5Y)Sensitivity to S&P 5002.05x0.57x2.20x1.03x
52-Week HighHighest price in past year$16.94$118.12$20.06$43.18
52-Week LowLowest price in past year$3.99$78.35$9.82$26.62
% of 52W HighCurrent price vs 52-week peak+28.7%+91.4%+83.9%+64.4%
RSI (14)Momentum oscillator 0–10043.848.369.845.0
Avg Volume (50D)Average daily shares traded341K244K1.5M669K
LMAT leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: OWLT as "Buy", LMAT as "Buy", NVCR as "Buy", ATRC as "Buy". Consensus price targets imply 311.5% upside for OWLT (target: $20) vs -5.9% for LMAT (target: $102). LMAT is the only dividend payer here at 0.73% yield — a key consideration for income-focused portfolios.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$20.00$101.50$33.50$50.67
# AnalystsCovering analysts5201519
Dividend YieldAnnual dividend ÷ price+0.7%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$0.79
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.8%
Insufficient data to determine a leader in this category.
Key Takeaway

LMAT leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ATRC leads in 1 (Valuation Metrics). 1 tied.

Best OverallLeMaitre Vascular, Inc. (LMAT)Leads 3 of 6 categories
Loading custom metrics...

OWLT vs LMAT vs NVCR vs ATRC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OWLT or LMAT or NVCR or ATRC a better buy right now?

For growth investors, Owlet, Inc.

(OWLT) is the stronger pick with 35. 4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). LeMaitre Vascular, Inc. (LMAT) offers the better valuation at 42. 8x trailing P/E (37. 2x forward), making it the more compelling value choice. Analysts rate Owlet, Inc. (OWLT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OWLT or LMAT or NVCR or ATRC?

On forward P/E, LeMaitre Vascular, Inc.

is actually cheaper at 37. 2x.

03

Which is the better long-term investment — OWLT or LMAT or NVCR or ATRC?

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -96. 5% for Owlet, Inc. (OWLT). Over 10 years, the gap is even starker: LMAT returned +608. 6% versus OWLT's -96. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OWLT or LMAT or NVCR or ATRC?

By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.

(LMAT) is the lower-risk stock at 0. 57β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 284% more volatile than LMAT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — OWLT or LMAT or NVCR or ATRC?

By revenue growth (latest reported year), Owlet, Inc.

(OWLT) is pulling ahead at 35. 4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -169. 9% for Owlet, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OWLT or LMAT or NVCR or ATRC?

LeMaitre Vascular, Inc.

(LMAT) is the more profitable company, earning 23. 1% net margin versus -39. 6% for Owlet, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OWLT or LMAT or NVCR or ATRC more undervalued right now?

On forward earnings alone, LeMaitre Vascular, Inc.

(LMAT) trades at 37. 2x forward P/E versus 370. 7x for AtriCure, Inc. — 333. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OWLT: 311. 5% to $20. 00.

08

Which pays a better dividend — OWLT or LMAT or NVCR or ATRC?

In this comparison, LMAT (0.

7% yield) pays a dividend. OWLT, NVCR, ATRC do not pay a meaningful dividend and should not be held primarily for income.

09

Is OWLT or LMAT or NVCR or ATRC better for a retirement portfolio?

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). Owlet, Inc. (OWLT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, OWLT: -96. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OWLT and LMAT and NVCR and ATRC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OWLT is a mid-cap high-growth stock; LMAT is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock. LMAT pays a dividend while OWLT, NVCR, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OWLT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 30%
Run This Screen
Stocks Like

LMAT

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 14%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

ATRC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 45%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform OWLT and LMAT and NVCR and ATRC on the metrics below

Revenue Growth>
%
(OWLT: 6.6% · LMAT: 11.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.